CU
LXEO icon

Cornell University’s Lexeo Therapeutics LXEO Stock Holding History

Cornell University’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-126,258
Closed -$1.98M – 4
2024
Q1 		$1.98M Buy
+126,258
New +$1.97M 30.03% 2

Other funds holding LXEO

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cornell University's LXEO Position: Q2 2024 in Review

Cornell University sold out of Lexeo Therapeutics (LXEO) in Q2 2024, closing a stake of 126,258 shares — an estimated $1.98M sold.

Cornell University first reported a position in LXEO in Q1 2024 and held it in 1 quarter. The position peaked at $1.98M in Q1 2024. 59 funds tracked by Wall St. Rank hold LXEO as of Q2 2024.

  • Cornell University reported no remaining Lexeo Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cornell University sold 126,258 Lexeo Therapeutics shares in Q2 2024, an estimated $1.98M.
  • Cornell University first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cornell University's Lexeo Therapeutics position peaked at $1.98M in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2024.

Based on Cornell University's 13F filing for Q2 2024, filed 13 Aug 2024.